JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (3): 72-76.doi: 10.6040/j.issn.1671-7554.0.2015.315

Previous Articles     Next Articles

Effects of rosiglitazone and GW9662 on the expression of PPAR-γ in JEG-3 cells

LI Zhishuang1, YU Qiong1, ZHANG Chunhua2   

  1. 1. Department of Pathology, Medical School of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Gynecology and Obstetrics, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2015-03-23 Online:2016-03-10 Published:2016-03-10

PDF (PC)

527

Abstract: Objective To investigate the effects of peroxisome proliferator-activated receptor gamma(PPAR-γ)agonist rosiglitazone and antagonist GW9662 on PPAR-γ expression and invasion ability of JEG-3 cells. Methods Immunohistochemistry method was used to detect PPAR-γ expression and distribution in normal chorionic, hydatidiform mole and choriocarcinoma tissues. Then PPAR-γ expression in rosiglitazone, GW9662 and control groups were examined respectively by Transwell assay, immunocytochemistry, Western blotting and qPCR method. Results PPAR-γ was expressed and distributed in cell nucleus of normal chorionic, hydatidiform mole and choriocarcinoma tissues, and its expression was significant down-regulated in choriocarcinoma tissues. Invasion ability of JEG-3 cells treated by rosiglitazone was decreased, while that of GW9662 group was increased. There was a statistical significance between the two groups(P<0.05). The expression of PPAR-γ in rosiglitazone group was lower than that in GW9662 group(P<0.05). Conclusion The activity of PPAR-γ is modulated via a negative feedback regulation mechanism by rosiglitazone and GW9662, and can influence the invasion ability of choriocarcinoma cells.

Key words: Peroxisome proliferator-activated receptor gamma, Choriocarcinoma, Rosiglitazone, GW9662

CLC Number: 

  • R737.33
[1] Khoo SK. Clinical aspects of gestational trophoblastic disease:a review based partly on 25-year experience of a statewide registry[J]. Aust N Z J Obstet Gynaecol, 2003, 43(4):280-289.
[2] Parast MM, Yu H, Ciric A, et al. PPARgamma regulates trophoblast proliferation and promotes labyrinthine trilineage differentiation[J]. PLoS One, 2009, 4(11):e8055. doi:10.1371/journal.pone.0008055.
[3] Marvin KW, Eykholt RL, Keelan JA, et al. The 15-deoxy-delta(12, 14)-prostaglandin J(2)receptor, peroxisome proliferator activated receptor-gamma(PPARgamma)is expressed in human gestational tissues and is functionally active in JEG3 choriocarcinoma cells[J]. Placenta, 2000, 21(4):436-440.
[4] Narala VR, Subramani PA, Narasimha VR, et al. The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation[J]. Int Immunopharmacol, 2014, 23(1):283-287.
[5] Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer[J]. Cancer Res, 2000, 60(4):1129-1138.
[6] Medina A, Ramos M, Amenedo M, et al. Choriocarcinoma syndrome[J]. Arch Esp Urol, 2014, 67(8):711-714.
[7] Suwaki N, Masuyama H, Masumoto A, et al. Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy[J]. Placenta, 2007, 28(4):315-323.
[8] Sanz MJ, Albertos F, Otero E, et al. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-gamma activation[J]. J Immunol, 2012, 189(1):411-424.
[9] 刘华, 陈昊, 唐照, 等. 全反式维甲酸通过DOK1/PPARγ信号通路抑制人乳腺癌细胞MCF-7的增殖[J]. 中国病理生理杂志, 2015, 31(7):1178-1183. LIU Hua, CHEN Hao, TANG Zhao, et al. All-trans retinoic acid supprewsses proliferation of breast cancer cells through DOK1/PPARγ pathway[J]. Chinese Journal of Pathophysiology, 2015, 31(7):1178-1183.
[10] Capparuccia L, Marzioni D, Giordano A, et al. PPARgamma expression in normal human placenta, hydatidiform mole and choriocarcinoma[J]. Mol Hum Reprod, 2002, 8(6):574-579.
[11] Ninomiya I, Yamazaki K, Oyama K, et al. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells[J]. Oncol Lett, 2014, 8(6):2709-2714.
[12] Choudhary R, Li H, Winn RA, et al. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail[J]. Neoplasia, 2010, 12(3):224-234.
[13] Yoshizumi T, Ohta T, Ninomiya I, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects[J]. Int J Oncol, 2004, 25(3):631-639.
[14] Apostoli AJ, Roche JM, Schneider MM, et al. Opposing roles for mammary epithelial-specific PPARgamma signaling and activation during breast tumour progression[J]. Mol Cancer, 2015, 14:85. doi:10.1186/s12943-015-0347-8.
[15] Wang Y, Tan H, Xu D, et al. The combinatory effects of PPAR-gamma agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells[J]. Int J Mol Med, 2014, 34(1):262-268.
[16] Levytska K, Drewlo S, Baczyk D, et al. PPAR- gamma Regulates Trophoblast Differentiation in the BeWo Cell Model[J]. PPAR Res, 2014, 2014:637251.
[1] LU Xiang-Dong, YANG Wei, XU Guang-Meng, QU Yuan-Ming. Expression and role of PPAR-γin meningiomas and troglitazone induced meningiomas cell apoptosis in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 65-.
[2] LI Jianhua, LI Zhan, JIA Xiaomeng, DU Juanjuan, MA Shenzhou, LIU Donglu, ZHANG Yong, ZHANG Yujiao, HOU Yinglong. Roles and mechanisms of TCONS_00016478 in atrial energy metabolic remodeling by regulating PGC-1α/ PPARγ pathway in rabbit models of atrial fibrillation [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 1-8.
[3] HOU Qiaoni, MA Huiming, XIANG Li, HE Yantao, XU Xian, CHEN Dongmei, ZHANG Xueyu. Effects of human placenta mesenchymal stem cell transplantation on ovarian function in premature ovarian failure in rats [J]. Journal of Shandong University (Health Sciences), 2019, 57(2): 52-60.
[4] CHU Qian-qian1, XU Gang2, REN Gui-jie1, XU Xia1, HU Zhong-yi1, LIU Yong-qing1, YUAN Hui-qing1, TIAN Ke-li1. Effect of rosiglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, in sensitizing 5-fluorouracil chemotherapy for colon cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 66-71.
[5] CHE Xiao-qi, LI Yin-yin, WANG Zhe, CHEN Hai-yan, ZHOU Jie. Effects of improved insulin resistance on the level of serum  glucagon-like peptide-1 in type 2 diabetic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(6): 5-7.
[6] ZU Zengyan1, ZHANG Guiyu1, MA Benhong1, WANG Hongxia2 . Inhibitory effect of rosiglitazone combined with cisplatin on the growth of endometrial carcinoma in Nude Mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(5): 62-66.
[7] LU Xiang-Dong, YANG Wei, XU Guang-Meng, QU Yuan-Ming. Expression and role of PPAR-γin meningiomas and troglitazone induced meningiomas cell apoptosis in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(6): 65-.
[8] . Effects of the Rosiglitazone on expressions of MMP2 and TIMP1 mRNA in hepatic stellate cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(11): 74-75.
[9]

SUN Ying1，2， LIU Yi3，　ZHANG Jie2，　CUI Bin2，　KONG Lei1，　ZHAO Jiajun1

.

Effects of Rosiglitazone on activities of AMPK
in the skeletal muscle of highfat fed rats

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(03): 48-52.
[10] LI Yan1,2, WANG Yi1, HUANG Lei2, AN Xiangmei2, ZHOU Yaping2
.

Effect of different interventional modalities on expression of resistin in dietinduced hyperresistinemia in rats

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(03): 39-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd